Spark Therapeutics (ONCE) Reaches $66.46 After 8.00% Down Move; Profile of 1 Analysts Covering Imperial Oil Ltd (TSE:IMO)

November 14, 2017 - By Clifton Ray

Among 7 analysts covering Imperial Oil Limited (TSE:IMO), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. Imperial Oil Limited had 29 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Sector Perform” rating by Scotia Capital given on Monday, May 1. The stock of Imperial Oil Ltd (TSE:IMO) earned “Sector Perform” rating by Scotia Capital on Wednesday, February 1. The company was maintained on Monday, June 6 by Raymond James. IBC upgraded the stock to “Sector Outperformer” rating in Friday, August 14 report. The rating was maintained by Scotia Capital on Thursday, September 22 with “Sector Perform”. Raymond James maintained Imperial Oil Ltd (TSE:IMO) on Tuesday, January 31 with “Market Perform” rating. The stock has “Outperform” rating by Credit Suisse on Monday, October 24. The firm earned “Sector Perform” rating on Thursday, September 22 by RBC Capital Markets. RBC Capital Markets maintained it with “Sector Perform” rating and $42 target in Wednesday, February 3 report. Desjardins Securities maintained Imperial Oil Ltd (TSE:IMO) on Tuesday, June 28 with “” rating. See Imperial Oil Ltd (TSE:IMO) latest ratings:

04/08/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $41.00 New Target: $40.00 Target Down

The stock of Spark Therapeutics Inc (NASDAQ:ONCE) is a huge mover today! About 458,205 shares traded. Spark Therapeutics Inc (NASDAQ:ONCE) has risen 13.53% since November 14, 2016 and is uptrending. It has underperformed by 3.17% the S&P500.The move comes after 5 months negative chart setup for the $2.46B company. It was reported on Nov, 14 by Barchart.com. We have $61.14 PT which if reached, will make NASDAQ:ONCE worth $196.80 million less.

Imperial Oil Limited is an integrated oil company. The company has market cap of $33.49 billion. The Firm is engaged in all the phases of the petroleum industry in Canada, including exploration for, and production and sale of, natural gas and crude oil. It has a 16.39 P/E ratio. The Company’s activities are conducted in three divisions: Upstream, Downstream and Chemical.

About 320,478 shares traded. Imperial Oil Ltd (TSE:IMO) has 0.00% since November 14, 2016 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 1.81 in Q2 2017. Its up 0.61, from 1.2 in 2017Q1. It improved, as 7 investors sold Spark Therapeutics Inc shares while 29 reduced holdings. 19 funds opened positions while 46 raised stakes. 27.22 million shares or 1.96% more from 26.70 million shares in 2017Q1 were reported. Glenmede Trust Com Na holds 0% or 8,302 shares. Ghost Tree Limited Company invested in 35,000 shares or 0.43% of the stock. Balyasny Asset Mgmt Limited Liability Corp holds 0.01% or 59,400 shares in its portfolio. Swiss Financial Bank has 0% invested in Spark Therapeutics Inc (NASDAQ:ONCE) for 39,200 shares. Legal General Group Inc Public Limited Liability Co invested in 8,931 shares. Bnp Paribas Arbitrage Sa has invested 0% in Spark Therapeutics Inc (NASDAQ:ONCE). Aqr Capital Mgmt Ltd reported 9,894 shares. 15,000 are owned by Polar Cap Llp. Fmr Limited Liability Company holds 0.03% or 4.67M shares in its portfolio. Dekabank Deutsche Girozentrale accumulated 13,800 shares. Clearbridge Limited Co holds 0.04% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE) for 669,752 shares. Envestnet Asset Mgmt stated it has 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE). Northern Trust Corporation holds 0% of its portfolio in Spark Therapeutics Inc (NASDAQ:ONCE) for 287,458 shares. Evercore Wealth Mgmt Limited Com accumulated 3,000 shares or 0.01% of the stock. Ubs Asset Americas reported 175,063 shares or 0% of all its holdings.

Among 20 analysts covering Spark Therapeutics (NASDAQ:ONCE), 17 have Buy rating, 1 Sell and 2 Hold. Therefore 85% are positive. Spark Therapeutics had 43 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Monday, July 17 with “Buy”. As per Wednesday, August 2, the company rating was maintained by Stifel Nicolaus. The firm earned “Sell” rating on Wednesday, September 2 by Zacks. On Tuesday, November 7 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Roth Capital maintained the shares of ONCE in report on Monday, October 5 with “Buy” rating. Barclays Capital maintained the shares of ONCE in report on Friday, October 13 with “Overweight” rating. The stock has “Hold” rating by Chardan Capital Markets on Thursday, July 20. The stock of Spark Therapeutics Inc (NASDAQ:ONCE) has “Buy” rating given on Tuesday, July 11 by Jefferies. The company was upgraded on Wednesday, August 2 by BMO Capital Markets. The rating was initiated by Goldman Sachs on Wednesday, March 30 with “Neutral”.

Analysts await Spark Therapeutics Inc (NASDAQ:ONCE) to report earnings on February, 28. They expect $-1.76 earnings per share, down 44.26% or $0.54 from last year’s $-1.22 per share. After $-1.90 actual earnings per share reported by Spark Therapeutics Inc for the previous quarter, Wall Street now forecasts -7.37% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>